S
Saral Desai
Researcher at Tata Memorial Hospital
Publications - 42
Citations - 771
Saral Desai is an academic researcher from Tata Memorial Hospital. The author has contributed to research in topics: Sarcoma & Cancer. The author has an hindex of 15, co-authored 40 publications receiving 659 citations.
Papers
More filters
Journal ArticleDOI
Crizotinib: A comprehensive review.
TL;DR: The history, mechanism of action, uses, adverse effects, dose modifications and future challenges and opportunities for patients with ALK-positive lung cancers are discussed.
Journal ArticleDOI
Pathology of Ewing's sarcoma/PNET: Current opinion and emerging concepts.
Saral Desai,Nirmala A. Jambhekar +1 more
TL;DR: In this paper, the pathology, biology, and molecular aspects of Ewing's sarcoma/PNET and their clinical and therapeutic implications are discussed. But translocation analyses are being used not only for the diagnosis and classification of small round cell tumors, but also to ascertain their prognostic significance, detect micrometastasis, and monitor minimal residual disease, with potential for targeted therapy.
Journal ArticleDOI
Frequency of EGFR Mutations in 907 Lung Adenocarcioma Patients of Indian Ethnicity
Anuradha Chougule,Kumar Prabhash,Vanita Noronha,Amit Joshi,Abhishek Thavamani,Pratik Chandrani,Pawan Upadhyay,Sagarika Utture,Saral Desai,Nirmala A. Jambhekar,Amit Dutt +10 more
TL;DR: The intermediate frequency of EGFR mutation among Indian population compared to Caucasians and East Asians is reminiscent of an ancestral admixture of genetic influence from Middle Easterners, Central Asians, and Europeans on modern- Indian population that may confer differential susceptibility to somatic mutations in EGFR.
Journal ArticleDOI
EGFR mutations in Indian lung cancer patients: clinical correlation and outcome to EGFR targeted therapy.
Vanita Noronha,Kumar Prabhash,Abhishek Thavamani,Anuradha Chougule,Nilendu Purandare,Amit Joshi,Rashmi Sharma,Saral Desai,Nirmala Jambekar,Amit Dutt,Rita Mulherkar +10 more
TL;DR: EGFR mutation is emphasized as an important predictive marker for response to oral tyrosine kinase inhibitors in the Indian population as well as a statistically significant difference in progression free survival.
Journal ArticleDOI
Chondromyxoid fibromas: a study of 10 cases.
Saral Desai,Nirmala A. Jambhekar,Sagarika Samanthray,Nikhil H. Merchant,Ajay Puri,Manish Agarwal +5 more
TL;DR: The study emphasizes that despite nuclear atypia and recurrences, CMF is a benign disease.